OAM
LGND icon

Oberweis Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Oberweis Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,911
Closed -$243K – 211
2019
Q3 		$243K Sell
3,911
-2,084
-35% -$131K 0.05% 179
2019
Q2 		$427K Sell
5,995
-65,577
-92% -$4.83M 0.08% 156
2019
Q1 		$5.61M Buy
71,572
+2,276
+3% +$172K 1.13% 23
2018
Q4 		$5.87M Buy
69,296
+12,250
+21% +$1.31M 1.31% 20
2018
Q3 		$9.77M Sell
57,046
-21,705
-28% -$3.27M 1.89% 8
2018
Q2 		$10.2M Buy
78,751
+537
+0.7% +$59.9K 2.56% 2
2018
Q1 		$8.06M Sell
78,214
-16,927
-18% -$1.67M 2.12% 8
2017
Q4 		$8.13M Buy
95,141
+12,583
+15% +$1.09M 1.9% 11
2017
Q3 		$7.01M Buy
82,558
+3,286
+4% +$260K 1.95% 14
2017
Q2 		$6M Sell
79,272
-2,356
-3% -$165K 1.65% 17
2017
Q1 		$5.39M Sell
81,628
-43,281
-35% -$2.85M 1.59% 24
2016
Q4 		$7.92M Buy
124,909
+6,027
+5% +$380K 2.37% 8
2016
Q3 		$7.57M Sell
118,882
-16,479
-12% -$1.21M 2.18% 11
2016
Q2 		$10.1M Sell
135,361
-11,742
-8% -$871K 2.99% 4
2016
Q1 		$9.83M Sell
147,103
-15,004
-9% -$912K 2.84% 5
2015
Q4 		$11M Buy
162,107
+9,234
+6% +$570K 3.08% 7
2015
Q3 		$8.17M Buy
152,873
+3,302
+2% +$200K 2.38% 13
2015
Q2 		$9.41M Sell
149,571
-51,424
-26% -$2.81M 2.49% 9
2015
Q1 		$9.67M Sell
200,995
-59,311
-23% -$2.27M 2.72% 6
2014
Q4 		$8.64M Sell
260,306
-9,538
-4% -$310K 2.58% 11
2014
Q3 		$7.91M Sell
269,844
-13,626
-5% -$452K 2.17% 14
2014
Q2 		$11M Sell
283,470
-59,150
-17% -$2.4M 2.72% 7
2014
Q1 		$14.4M Buy
342,620
+673
+0.2% +$28.1K 3.02% 6
2013
Q4 		$11.2M Buy
341,947
+103,850
+44% +$3.38M 2.72% 6
2013
Q3 		$6.43M Buy
238,097
+215,655
+961% +$6.07M 1.83% 23
2013
Q2 		$524K Buy
+22,442
New +$404K 0.15% 100

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Oberweis Asset Management's LGND Position: Q4 2019 in Review

Oberweis Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 3,911 shares — an estimated $243K sold.

Oberweis Asset Management first reported a position in LGND in Q2 2013 and held it in 26 quarters. The position peaked at $14.4M in Q1 2014. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

  • Oberweis Asset Management reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Oberweis Asset Management sold 3,911 Ligand Pharmaceuticals shares in Q4 2019, an estimated $243K.
  • Oberweis Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 26 quarters.
  • Oberweis Asset Management's Ligand Pharmaceuticals position peaked at $14.4M in Q1 2014.
  • 266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Oberweis Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.